RETA Reata Pharmaceuticals Inc

Price (delayed)

$31.08

Market cap

$1.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.35

Enterprise value

$742.88M

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. ...

Highlights
RETA's quick ratio has soared by 79% YoY and by 12% QoQ
Reata Pharmaceuticals's revenue has increased by 33% YoY
The company's equity has shrunk by 65% YoY and by 31% QoQ
The net income has contracted by 14% YoY and by 2.1% from the previous quarter

Key stats

What are the main financial stats of RETA
Market
Shares outstanding
36.46M
Market cap
$1.13B
Enterprise value
$742.88M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.85
Price to sales (P/S)
98.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.83
Earnings
Revenue
$11.46M
EBIT
-$253.83M
EBITDA
-$252.6M
Free cash flow
-$250.3M
Per share
EPS
-$8.35
Free cash flow per share
-$6.87
Book value per share
$3.51
Revenue per share
$0.31
TBVPS
$18.67
Balance sheet
Total assets
$679.87M
Total liabilities
$552.08M
Debt
$141.59M
Equity
$127.79M
Working capital
$493.72M
Liquidity
Debt to equity
1.11
Current ratio
12.32
Quick ratio
12.2
Net debt/EBITDA
1.55
Margins
EBITDA margin
-2,204.3%
Gross margin
100%
Net margin
-2,651%
Operating margin
-2,215.1%
Efficiency
Return on assets
-41.6%
Return on equity
-137.5%
Return on invested capital
-374.9%
Return on capital employed
-39.9%
Return on sales
-2,215.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RETA stock price

How has the Reata Pharmaceuticals stock price performed over time
Intraday
-6.67%
1 week
0.42%
1 month
14.73%
1 year
-78.17%
YTD
17.86%
QTD
-5.13%

Financial performance

How have Reata Pharmaceuticals's revenue and profit performed over time
Revenue
$11.46M
Gross profit
$11.46M
Operating income
-$253.83M
Net income
-$303.77M
Gross margin
100%
Net margin
-2,651%
Reata Pharmaceuticals's revenue has increased by 33% YoY
Reata Pharmaceuticals's gross profit has increased by 33% YoY
The operating income is down by 19% YoY and by 3.7% from the previous quarter
The net income has contracted by 14% YoY and by 2.1% from the previous quarter

Growth

What is Reata Pharmaceuticals's growth rate over time

Valuation

What is Reata Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.85
P/S
98.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.83
Reata Pharmaceuticals's EPS has decreased by 8% YoY
The company's equity has shrunk by 65% YoY and by 31% QoQ
The stock's price to book (P/B) is 16% less than its last 4 quarters average of 11.3
The P/S is 62% below the last 4 quarters average of 279.0 and 41% below the 5-year quarterly average of 179.6
Reata Pharmaceuticals's revenue has increased by 33% YoY

Efficiency

How efficient is Reata Pharmaceuticals business performance
The ROE has shrunk by 56% YoY and by 30% QoQ
RETA's return on assets is down by 15% year-on-year and by 7% since the previous quarter
Reata Pharmaceuticals's ROS has increased by 11% YoY but it has decreased by 4% from the previous quarter

Dividends

What is RETA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RETA.

Financial health

How did Reata Pharmaceuticals financials performed over time
RETA's total assets is 23% more than its total liabilities
RETA's quick ratio has soared by 79% YoY and by 12% QoQ
The current ratio has surged by 75% year-on-year and by 11% since the previous quarter
Reata Pharmaceuticals's debt is 11% more than its equity
The company's equity has shrunk by 65% YoY and by 31% QoQ
The debt to equity has soared by 52% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.